Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio observacional, prospectivo y multicéntrico a largo plazo para recopilar en una población real datos sobre el patrón de tratamiento de secukinumAb en pacientes adultos con hidradenitis supurativa de moderada a grave. (ANIMA)

13 de noviembre de 2026 actualizado por: Novartis Pharmaceuticals

ESTUDIO OBSERVACIONAL, PROSPECTIVO, MULTICÉNTRICO A LARGO PLAZO PARA RECOPILAR EN UNA POBLACIÓN REAL DATOS SOBRE EL PATRÓN DE TRATAMIENTO DE SECUKINUMAB EN PACIENTES ADULTOS CON HIDRADENITIS SUPURATIVA (HS) DE MODERA A GRAVE (ANIMA)

The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Descripción detallada

The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.

In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.

Tipo de estudio

De observación

Inscripción (Actual)

436

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Aachen, Alemania, 52064
        • Novartis Investigative Site
      • Ahaus, Alemania, 48683
        • Novartis Investigative Site
      • Annaberg-Buchholz, Alemania, 09456
        • Novartis Investigative Site
      • Bad Steben, Alemania, 95138
        • Novartis Investigative Site
      • Baden-Baden, Alemania, 76530
        • Novartis Investigative Site
      • Berlin, Alemania, 12159
        • Novartis Investigative Site
      • Berlin, Alemania, 13595
        • Novartis Investigative Site
      • Bielefeld, Alemania, 33647
        • Novartis Investigative Site
      • Bochum, Alemania, 44791
        • Novartis Investigative Site
      • Bonn, Alemania, 53105
        • Novartis Investigative Site
      • Brandenburg, Alemania, 14776
        • Novartis Investigative Site
      • Bremen, Alemania, 28359
        • Novartis Investigative Site
      • Buxtehude, Alemania, 21614
        • Novartis Investigative Site
      • Bückeburg, Alemania, 31675
        • Novartis Investigative Site
      • Chemnitz, Alemania, 09117
        • Novartis Investigative Site
      • Chemnitz, Alemania, 09113
        • Novartis Investigative Site
      • Cologne, Alemania, 51065
        • Novartis Investigative Site
      • Delitzsch, Alemania, 04509
        • Novartis Investigative Site
      • Dessau, Alemania, 06847
        • Novartis Investigative Site
      • Dorsten, Alemania, 46282
        • Novartis Investigative Site
      • Dortmund, Alemania, 44137
        • Novartis Investigative Site
      • Dresden, Alemania, 01309
        • Novartis Investigative Site
      • Düren, Alemania, 52349
        • Novartis Investigative Site
      • Emsdetten, Alemania, 48282
        • Novartis Investigative Site
      • Erlangen, Alemania, 91054
        • Novartis Investigative Site
      • Falkenberg, Alemania, 04895
        • Novartis Investigative Site
      • Falkensee, Alemania, 14612
        • Novartis Investigative Site
      • Freising, Alemania, 85354
        • Novartis Investigative Site
      • Geilenkirchen, Alemania, 52511
        • Novartis Investigative Site
      • Gera, Alemania, 07548
        • Novartis Investigative Site
      • Gernsbach, Alemania, 76593
        • Novartis Investigative Site
      • Gladbeck, Alemania, 45964
        • Novartis Investigative Site
      • Großenhain, Alemania, 01558
        • Novartis Investigative Site
      • Hamburg, Alemania, 20246
        • Novartis Investigative Site
      • Hamburg, Alemania, 22143
        • Novartis Investigative Site
      • Hanover, Alemania, 30159
        • Novartis Investigative Site
      • Haslach im Kinzigtal, Alemania, 77716
        • Novartis Investigative Site
      • Hofgeismar, Alemania, 34369
        • Novartis Investigative Site
      • Jena, Alemania, 07743
        • Novartis Investigative Site
      • Jülich, Alemania, 52428
        • Novartis Investigative Site
      • Karlsruhe, Alemania, 76133
        • Novartis Investigative Site
      • Kempen, Alemania, 47906
        • Novartis Investigative Site
      • Lübeck, Alemania, 23538
        • Novartis Investigative Site
      • Magdeburg, Alemania, 39120
        • Novartis Investigative Site
      • Magdeburg, Alemania, 39104
        • Novartis Investigative Site
      • Mainz, Alemania, 55116
        • Novartis Investigative Site
      • Marburg, Alemania, 35043
        • Novartis Investigative Site
      • Minden, Alemania, 32429
        • Novartis Investigative Site
      • Mönchengladbach, Alemania, 41063
        • Novartis Investigative Site
      • Neu Wulmstorf, Alemania, 21629
        • Novartis Investigative Site
      • Nuremberg, Alemania, 90419
        • Novartis Investigative Site
      • Oberasbach, Alemania, 90522
        • Novartis Investigative Site
      • Oelde, Alemania, 59302
        • Novartis Investigative Site
      • Peitz, Alemania, 03185
        • Novartis Investigative Site
      • Potsdam, Alemania, 14469
        • Novartis Investigative Site
      • Remscheid, Alemania, 42897
        • Novartis Investigative Site
      • Selters, Alemania, 56242
        • Novartis Investigative Site
      • Simmern, Alemania, 55469
        • Novartis Investigative Site
      • Soest, Alemania, 59494
        • Novartis Investigative Site
      • Stolberg, Alemania, 52222
        • Novartis Investigative Site
      • Unna, Alemania, 59423
        • Novartis Investigative Site
      • Wittlich, Alemania, 54316
        • Novartis Investigative Site
      • Wuppertal, Alemania, 42103
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Alemania, 79068
        • Novartis Investigative Site
      • Rheinstetten, Baden-Wurttemberg, Alemania, 76287
        • Novartis Investigative Site
    • Bavaria
      • Haßfurt, Bavaria, Alemania, 97437
        • Novartis Investigative Site
      • Kulmbach, Bavaria, Alemania, 95326
        • Novartis Investigative Site
      • Lauf an der Pegnitz, Bavaria, Alemania, 91207
        • Novartis Investigative Site
      • Nuremberg, Bavaria, Alemania, 90402
        • Novartis Investigative Site
    • Brandenburg
      • Panketal, Brandenburg, Alemania, 16341
        • Novartis Investigative Site
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Alemania, 22549
        • Novartis Investigative Site
    • Lower Saxony
      • Lingen, Lower Saxony, Alemania, 49809
        • Novartis Investigative Site
    • Mecklenburg-Vorpommern
      • Bergen auf Rügen, Mecklenburg-Vorpommern, Alemania, 18528
        • Novartis Investigative Site
      • Kröpelin, Mecklenburg-Vorpommern, Alemania, 18236
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Krefeld, North Rhine-Westphalia, Alemania, 47798
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Mainz, Rhineland-Palatinate, Alemania, 55128
        • Novartis Investigative Site
    • Saxony
      • Dresden, Saxony, Alemania, 01307
        • Novartis Investigative Site
      • Leipzig, Saxony, Alemania, 04207
        • Novartis Investigative Site
      • Leipzig, Saxony, Alemania, 04289
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Wittenberg, Saxony-Anhalt, Alemania, 06886
        • Novartis Investigative Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Descripción

Inclusion Criteria:

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  1. Patients who provide written informed consent to participate in the study
  2. Male and female patients with ≥18 years of age
  3. Diagnosis of clinically unequivocal moderate to severe HS
  4. Patients for whom a therapy with secukinumab is medically indicated
  5. Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
  6. Treatment with secukinumab according to the latest version of SmPC
  7. Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:

  1. Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
  2. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
  4. Previous exposure to IL-17 inhibitors
  5. For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
secukinumab

Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.

Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of patients receiving up-titration
Periodo de tiempo: Up to 24 months

Proportion of patients receiving up-titration (q4w-to-q2w)

Up to 24 months
Proportion of patients receiving down-titration
Periodo de tiempo: Up to 24 months

Proportion of patients receiving down-titration (q2w-to-q4w)

Up to 24 months
Time to up-titration and down-titration
Periodo de tiempo: Up to 2 years

Time to up-titration and down-titration

Up to 2 years
Duration of q4w treatment with secukinumab after dose reduction
Periodo de tiempo: Up to 2 years

Duration of q4w treatment with secukinumab after dose reduction

Up to 2 years
Proportion of patients who receive more than one up-and/or down titration
Periodo de tiempo: Up to 24 months

Proportion of patients who receive more than one up-and/or down titration

Up to 24 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Periodo de tiempo: Up to 2 years

Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

Up to 2 years
Number and type of surgical interventions
Periodo de tiempo: Up to 2 years

Number and type of surgical interventions

  • minor and major surgical excision;
  • inpatient, outpatient
Up to 2 years
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Periodo de tiempo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Periodo de tiempo: Up to 24 months

The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity.

HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

Up to 24 months
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Periodo de tiempo: Up to 24 months

The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school.

Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment.

Up to 24 months
Mean reduction of Abscesses and inflammatory nodules (AN) count
Periodo de tiempo: Up to 24 months

Mean reduction of Abscesses and inflammatory nodules (AN) count

Up to 24 months
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Periodo de tiempo: Up to 24 months

The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form.

Up to 24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

10 de agosto de 2023

Finalización primaria (Estimado)

31 de marzo de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de junio de 2023

Primero enviado que cumplió con los criterios de control de calidad

26 de junio de 2023

Publicado por primera vez (Actual)

28 de junio de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir